Investing Profile

Stacie Weninger

InvestorVC
Executive Director at F-Prime
Photo of Stacie Weninger, F-Prime Capital Partners

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Harvard University Network
771 CONNECTIONS
Harvard University Network
119 CONNECTIONS
Fidelity Investments Network
63 CONNECTIONS
F-Prime Network
41 CONNECTIONS
cb
$100K - $10.0M
$5.0M
7
CompanyStageDateRound SizeTotal Raised
Atalanta Therapeutics
Series BJan 2025$97M
Series AJan 2021$110M
$210M
Co-investors: Jessica Alston (F-Prime Capital Partners), Stephen Knight (F-Prime Capital Partners), Niall O’Donnell (RiverVest Venture Partners), Jason P. Hafler (Sanofi Ventures)
Tenvie Therapeutics
Series AJan 2025$200M
$200M
Co-investors: Paul Berns (ARCH Venture Partners), Kristina Burow (ARCH Venture Partners), Alaa Halawa (Vir Biotechnology, Inc.)
Engrail Therapeutics
Series BMar 2024$170M
$230M
Co-investors: Heath Lukatch (Novo Holdings), Peter Bisgaard (Nan Fung Life Sciences), Jasper Bos (Forbion), Niall O’Donnell (RiverVest Venture Partners)
Neumora Therapeutics
Series AOct 2021$400M
$510M
Co-investors: Robert Nelsen (ARCH Venture Partners), Kristina Burow (ARCH Venture Partners), Alaa Halawa (Vir Biotechnology, Inc.)
Denali Therapeutics
Series BAug 2016$130M
Series AMay 2015$220M
$350M
Co-investors: Doug Cole (Flagship Pioneering), Robert Nelsen (ARCH Venture Partners)
Executive Director F-PrimePresent
Science Program Director Fidelity InvestmentsPresent
Executive Director F-Prime Biomedical Research InitiativePresent
Senior Scientist, Neuron Cell PressPresent
Senior Analyst and Project Manager, Task Force on Women in Science Harvard UniversityPresent
Harvard University Doctor of Philosophy (Ph.D.) Neuroscience
Sign in with Google →
Sign in with Google →